Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis
– Full data from Phase 2b CONTROL study presented at 2022 Winter Clinical Dermatology Conference – – Company plans to […]